Audentes therapeutics, inc. (BOLD)
CashFlow / Yearly
Dec'18Dec'17Dec'16Dec'15Dec'14
Cash flows from operating activities:
Net loss

-128,821

-90,238

-59,668

-26,458

-10,819

Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of discount on investments

-

-

-

-

0

Depreciation and amortization

5,595

3,398

1,630

166

35

Stock-based compensation

16,495

6,880

2,004

1,291

515

Deferred income taxes

0

-2,246

0

0

-

Accretion of discount on marketable securities

1,861

350

-51

-660

-

Accretion of asset retirement obligation

50

34

106

136

0

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

-2,298

263

102

131

0

Other

-555

-337

-71

0

9

Changes in operating assets and liabilities:
Restricted cash

-

-

-

3,610

0

Prepaid expenses and other current assets

2,150

675

-1,085

3,188

300

Other assets

3,260

2,012

-27

195

36

Accounts payable

4,081

686

-671

628

857

Accrued liabilities

2,017

-1,579

4,815

2,634

1,683

Deferred rent

-1,619

-937

-1,522

-290

-5

Net cash used in operating activities

-107,978

-84,565

-48,926

-27,515

-8,069

Cash acquired from acquisition

-

-

-

142

0

Purchases of property and equipment

11,609

7,551

16,651

1,686

125

Proceeds from sales of property and equipment

0

0

16

0

0

Proceeds from maturities of marketable securities

208,586

126,828

58,624

32,792

0

Purchases of marketable securities

382,025

152,713

104,037

40,124

16,539

Net cash used in investing activities

-185,048

-33,436

-62,048

-8,876

-16,664

Proceeds from exercise of stock options and ESPP purchases

4,049

828

157

70

0

Proceeds from issuance of common stock, net of issuance costs

394,413

119,725

75,208

0

0

Net cash provided by financing activities

398,462

120,553

75,365

62,850

57,386

Net (decrease) increase in cash, cash equivalents and restricted cash

105,436

2,552

-35,609

26,459

32,653

Noncash investing and financing activities:
Change in accounts payable and accrued liabilities related to property and equipment purchases

2,407

1,239

927

1,140

65

Issuance of common stock warrant related to debt financing facility

0

83

0

0

-

Conversion of redeemable convertible preferred stock to common stock at closing of initial public offering

0

0

135,750

0

0

Deferred financing costs for follow-on offering

136

0

2,333

0

0

Preferred stock issuance costs

-

-

-

140

-120

Issuance of common stock in exchange for license

-

-

-

128

0